Phase 3 Obesity Clinical Trials
23 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 23 trials
Recruiting
Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
ObesityOverweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Hudson Biotech2,539 enrolled1 locationNCT07481747
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled3 locationsNCT07351058
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight
Hoffmann-La Roche2,000 enrolled2 locationsNCT07351045
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled193 locationsNCT06937086
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ObesityOverweight
Eli Lilly and Company900 enrolled178 locationsNCT07392190
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
ObesityOverweight
Eli Lilly and Company600 enrolled35 locationsNCT07357415
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled158 locationsNCT07282600
Recruiting
Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled188 locationsNCT06937099
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
HypertensionOverweight or Obesity
Eli Lilly and Company487 enrolled99 locationsNCT06948435
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled564 locationsNCT07037459
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
ObesityOverweight
Eli Lilly and Company600 enrolled80 locationsNCT06972459
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company1,200 enrolled80 locationsNCT06993792
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company250 enrolled31 locationsNCT07232719
Recruiting
Phase 3
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
Obesity, Overweight
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.825 enrolled1 locationNCT07279194
Recruiting
Phase 3
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Atrial FibrillationOverweight or Obesity
University of Chicago200 enrolled2 locationsNCT06499857
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company600 enrolled77 locationsNCT06972472
Recruiting
Phase 2Phase 3
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
Diabetes Mellitus, Type 2Heart Failure With Preserved Ejection FractionHeart Failure, Diastolic+2 more
University of Leicester63 enrolled3 locationsNCT05887271
Recruiting
Phase 3
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
ObesityHIV (Human Immunodeficiency Virus)Overweight and/or Obesity
José Antonio Mata Marín306 enrolled1 locationNCT07075146
Recruiting
Phase 2Phase 3
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
ObesityEndometrial NeoplasmsAtypical Endometrial Hyperplasia+1 more
Xiaojun Chen29 enrolled2 locationsNCT06379113